Product Development

IP Development: StructuredIP™

Creating what’s next in healthcare

As a global leader in the healthcare and life science industry, Alira Health has a clear vision of what’s next in the patient care market.

We bring this expertise to our StructuredIP™ process to ensure that your IP is novel, inventive, broad, and innovative to make certain your portfolio has the most commercial value and is best aligned with your overall business strategy.

We also provide expert witnesses to support patent litigation for biologic products. Our CMC specialists often serve as expert witnesses for companies intending to protect or challenge IP on biologic products.

IP that improves outcomes

We employ the full breadth of our healthcare and life science skills to develop IP that solves problems, improves health, and is worthy of your investment. We are an industry-leader in IP for:
  • Pharmaceuticals and Life Sciences
    Our team of experts can help you innovate early stage biotech, RX, pharmaceuticals, and OTC products. With decades of experience, we understand the science behind the cause of disease
  • Medical Devices and Healthcare IT
    Our team of scientists and doctors know what caregivers and payers need to diagnose, monitor, manage, and treat disease

Why choose Alira Health?

As your partner, we can assist in new IP development as well as IP portfolio management and due diligence for investors and strategic partners. We’ll work closely with you on:

  • Development of new IP
  • Competition and competitive landscape evaluation
  • Patent writing and claim set analysis
  • Technical due diligence for investments and M&A
  • IP portfolio management

Related news

Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.